AI-driven genomic analysis platform for cancer and rare disease diagnostics
SOPHiA GENETICS builds an AI platform that transforms genomic and multimodal clinical data into diagnostic insights for oncology and rare inherited disorders. The stack reveals a hybrid architecture: Salesforce + Pardot on the go-to-market side, paired with Azure Kubernetes and Python/R for data processing — a pattern typical of companies scaling clinical software globally. Active hiring across sales (13), engineering (7), and research (6) reflects simultaneous growth in commercial reach and platform capability, while heavy regulatory work (IVD→IVDR transition, EU clinical trial submissions, protocol optimizations) dominates the project backlog.
Notable leadership hires: Field Marketing Director, Interoperability and Integration Lead
Founded in 2011, SOPHiA GENETICS develops SOPHiA DDM, a platform for genomic and multimodal data analysis aimed at clinicians, researchers, and biopharma organizations. The company operates across three main fronts: diagnostic workflow integration for hospital systems, real-world data solutions, and regulatory compliance across EU and international markets. Based in Rolle, Switzerland, with offices across the US, Singapore, Malaysia, Germany, and France, the company is 201–500 employees and actively hiring across sales, engineering, research, and healthcare roles. Core challenges center on scaling high-volume medical data ingestion, integrating with fragmented hospital infrastructure, navigating complex regulatory transitions (IVDR compliance), and optimizing go-to-market operations.
Backend: Azure, Kubernetes, Python, R, Java, Node.js. Frontend: React, Next.js. Data: MySQL, MariaDB, DuckDB. Clinical interop: FHIR, SMART on FHIR. Sales/BI: Salesforce, Pardot, Power BI, Tableau. DevOps: GitLab CI/CD, Terraform.
Core projects: SOPHiA DDM platform expansion, clinical diagnostic workflow integration, real-world data solutions, multimodal analytics, and regulatory submissions (IVDR transition, EU clinical trial assays). Also: probe design improvements, pipeline architecture scaling, and commercial process optimization.
Other companies in the same industry, closest in size